Contemporary Treatment of Acute Heart Failure

Progress in Cardiovascular Diseases
Ruth Hsiao, Barry H Greenberg

Abstract

Heart failure (HF) is a rapidly growing global pandemic. A consequence of the increased prevalence of HF has been an increase in hospitalizations due to acute HF (AHF) in the United States and in many other countries around the world. Despite advances in treatment, morbidity and mortality rates in the post-discharge period after an AHF admission remain unacceptably high. The occurrence of an AHF episode poses a major clinical challenge since current therapeutic options are limited to providing mostly short-term symptomatic relief. Diuretics to relieve congestion, inotropic agents to maintain tissue perfusion and vasodilators to reduce the load on the heart are the primary drug approaches for treating AHF. Determining the most effective way of using these agents has been the focus of several recently completed studies, but success in altering outcomes has proved to be elusive. Results from studies using new experimental agents such as ularitide and serelaxin, however, have been promising and ongoing. Phase 3 clinical trials will determine their role in the therapeutic regimen. This manuscript reviews aspects of medical therapy of AHF for which new insights are available and describes pathophysiologic abnormalities that appear to...Continue Reading

References

Jan 4, 1979·The New England Journal of Medicine·E H SonnenblickT H LeJemtel
Feb 28, 1974·The New England Journal of Medicine·A Ramírez, W H Abelmann
Sep 19, 1974·The New England Journal of Medicine·N H GuihaC J Limas
Oct 1, 1993·Journal of the American College of Cardiology·K K HoD Levy
Jun 1, 1996·The American Journal of the Medical Sciences·J B ShipleyM L Hess
Mar 28, 2002·JAMA : the Journal of the American Medical Association·Michael S CuffeUNKNOWN Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigato
Aug 2, 2002·The New England Journal of Medicine·Satish KenchaiahRamachandran S Vasan
Dec 6, 2002·The New England Journal of Medicine·Gerard O'Brien
Jan 13, 2004·Journal of the American College of Cardiology·Daniel E FormanHarlan M Krumholz
Jan 29, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Uri ElkayamMahyar Derakhshani
Sep 27, 2005·The American Journal of Cardiology·Melike BayramMihai Gheorghiade
Nov 1, 2006·European Heart Journal·Veselin MitrovicMarkus Meyer
Nov 23, 2006·The American Journal of Medicine·Mihai GheorghiadeJohn Burnett
May 21, 2008·PharmacoEconomics·Lawrence LiaoDavid J Whellan
Apr 3, 2009·The New England Journal of Medicine·Stephen F JencksEric A Coleman
Jul 17, 2009·The New England Journal of Medicine·Eric C Rackow
Nov 21, 2009·Congestive Heart Failure·William Frank PeacockGregg C Fonarow
Mar 4, 2011·The New England Journal of Medicine·G Michael FelkerUNKNOWN NHLBI Heart Failure Clinical Research Network
Oct 20, 2011·JAMA : the Journal of the American Medical Association·Jersey ChenHarlan M Krumholz
Dec 20, 2011·Circulation·Véronique L RogerUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 13, 2012·European Journal of Heart Failure·Said LaribiUNKNOWN GREAT network
Nov 8, 2012·The New England Journal of Medicine·Bradley A BartUNKNOWN Heart Failure Clinical Research Network
Nov 13, 2012·Lancet·John R TeerlinkUNKNOWN RELAXin in Acute Heart Failure (RELAX-AHF) Investigators
Jan 10, 2013·Current Heart Failure Reports·Payman Zamani, Barry H Greenberg
Jan 24, 2013·JAMA : the Journal of the American Medical Association·Kumar DharmarajanHarlan M Krumholz
Jun 7, 2013·Circulation·UNKNOWN WRITING COMMITTEE MEMBERSUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Jul 10, 2013·Journal of Cardiac Failure·Michelle D Carlson, Peter M Eckman
Aug 31, 2013·Circulation Research·Véronique L Roger
Nov 20, 2013·JAMA : the Journal of the American Medical Association·Horng H ChenUNKNOWN NHLBI Heart Failure Clinical Research Network
Feb 18, 2014·Journal of the American College of Cardiology·Gary S FrancisSirtaz Adatya
Feb 12, 2015·European Heart Journal·Stefan D AnkerGerasimos Filippatos

❮ Previous
Next ❯

Citations

Aug 25, 2017·Nature Reviews. Disease Primers·Michelle W BloomJaved Butler
Aug 3, 2019·Journal of the Saudi Heart Association·Waleed AlHabeebWalid Hassan
Dec 28, 2019·Journal of Cardiothoracic and Vascular Anesthesia·Archit SharmaHarish Ramakrishna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Related Papers

Tennessee Medicine : Journal of the Tennessee Medical Association
Anuradha Tunuguntla
Current Emergency and Hospital Medicine Reports
V A KumarP D Levy
Journal of Pharmacy Practice
Sarah Hanigan, Robert J DiDomenico
© 2022 Meta ULC. All rights reserved